Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naive and relapsed/refractory patients with chronic lymphocytic leukemia

被引：0
|
作者：
Andersson, Maria
Mulder, Tom
Heimersson, Kia
Sonnert-Husa, Sonja
Giertz, Annika
Karlsson, Claes
Lundin, Jeanette
Hansson, Lotta
Osterborg, Anders
Palma, Marzia
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553105
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [31] A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
    Allan, John N.
    Kittai, Adam S.
    James, Dan
    Ridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Davids, Matthew S.
    Skarbnik, Alan
    BLOOD, 2023, 142
  • [32] Physical Fitness As A Determinant Of Leukemia Cell Biology In Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
    Bartlett, David B.
    Sitlinger, Andrea
    Deal, Michael
    Connelly, Margery A.
    Stewart, Tiffany
    Guadalupe, Eross
    MacDonald, Grace
    Kraus, William E.
    Weinberg, J. Brice
    Brander, Danielle B.
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2020, 52 (07) : 986 - 986
  • [33] Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier
    Keating, Michael J.
    Ferrajoli, Alessandra
    Lerner, Susan
    Wang, Xuemei
    O'Brien, Susan
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E35 - E35
  • [34] A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Ahn, Inhye E.
    Zhou, Yinglu
    Tyekucheva, Svitlana
    Cormier, Hannah
    Fernandes, Stacey M.
    Montegaard, Josie
    Kilcommons, Marykate
    Crombie, Jennifer L.
    Merryman, Reid W.
    Parry, Erin M.
    Armand, Philippe
    Fisher, David C.
    Jacobson, Caron A.
    Davids, Matthew S.
    Brown, Jennifer R.
    BLOOD, 2023, 142
  • [35] LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
    Autore, F.
    Strati, P.
    Innocenti, I.
    Corrente, F.
    Trentin, L.
    Cortelezzi, A.
    Visco, C.
    Coscia, M.
    Cuneo, A.
    Gozzetti, A.
    Mauro, F. R.
    Montillo, M.
    Gentile, M.
    Morabito, F.
    Molica, S.
    Falcucci, P.
    D'Arena, G.
    Murru, R.
    Vincelli, D.
    Galieni, P.
    Reda, G.
    Tisi, M. C.
    Vitale, C.
    Rigolin, G. M.
    Ferrajoli, A.
    Laurenti, L.
    HAEMATOLOGICA, 2017, 102 : 707 - 707
  • [36] Long-term outcomes of entecavir monotherapy in patients with treatment-naive chronic hepatitis B
    Kim, Hyung Joon
    Lee, Hyun Woong
    Park, Ji Hoon
    Lee, Kyeong Heon
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 248 - 249
  • [37] LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
    Autore, F.
    Strati, P.
    Innocenti, I.
    Corrente, F.
    Trentin, L.
    Cortelezzi, A.
    Visco, C.
    Coscia, M.
    Cuneo, A.
    Gozzetti, A.
    Mauro, F. R.
    Montillo, M.
    Gentile, M.
    Morabito, F.
    Molica, S.
    Falcucci, P.
    D'Arena, G.
    Murru, R.
    Vincelli, D.
    Galieni, P.
    Reda, G.
    Tisi, M. C.
    Vitale, C.
    Rigolin, G. M.
    Ferrajoli, A.
    Laurenti, L.
    HAEMATOLOGICA, 2017, 102 : 116 - 117
  • [38] Long-Term Outcome of Treatment-Naive and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab
    Sivina, Mariela
    Kim, Ekaterina
    Wierda, William G.
    Ferrajoli, Alessandra
    Jain, Nitin
    Thompson, Philip A.
    Estrov, Zeev E.
    Kantarjian, Hagop
    Keating, Michael J.
    Burger, Jan A.
    BLOOD, 2021, 138 : 3734 - +
  • [39] LONG-TERM HYDANTOIN TREATMENT AND CHRONIC LYMPHOCYTIC-LEUKEMIA
    DELSOL, G
    SEIGNEURIC, C
    DAMORAN, JA
    DBJAY, H
    REVUE DE MEDECINE DE TOULOUSE, 1980, 16 (04): : 206 - 206
  • [40] Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study
    Woyach, Jennifer A.
    Awan, Farrukh T.
    Jianfar, Mojgan
    Rogers, Kerry A.
    Jones, Jeffrey
    Covey, Todd
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2017, 130
12345